Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation
Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium), and Senior Clinical Academic, Professor Sir Robert Lechler, Senior Vice President/Provost (Health) and Executive Director of King's Health Partners Academic Health Sciences Centre, to its Board of Directors.